PREDICTING CARDIOVASCULAR RISK USING COMMON UTILIZATION MANAGEMENT CRITERIA FOR PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS IN COMMERCIALLY INSURED PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

A growing body of literature suggests significant difficulty in gaining access and reimbursement for proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), which are indicated for additional lowering of low density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic